EUCTR2021-000596-37-FR招募中1 期
A randomized phase I/ II multicenter study evaluating combination of luspatercept in LR-MDS without RS having failed or being ineligible to ESA - COMBOLA
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •Patients must meet all of the following criteria to participate in the study:
- •1. Myelodysplastic syndrome according to current WHO classification
- •2. Age = 18 years
- •3. Patients with lower risk MDS according to IPSS classification (LOW, INT-1) without RS who failed to achieved a response or who subsequently relapse after ESA (at least 60000 U EPO-a over at least 12weeks or equivalent), without disease progression (or ineligible to ESA defined by EPO > 500 UI/l)
- •4. Hemogobin < 9 gr/dl or Transfusion dependant (at least 3 RBCs in 16 wk in at least 2 transfusion episodes)
- •5. Non del(5q) syndrome
- •6. adequat renal function, defined by creatinine less than 1.5 times the upper limit of normal, creatinine clearance = 40 mL/min (MDRD formula).
- •7. adequat liver function, defined by total bilirubin and transaminases less than 1.5 times the upper limit of normal.
- •8. Patient is not known to be refractory to platelet transfusions.
- •9. Written informed consent.
- •10. Patient must understand and voluntarily sign consent form.
- •11. Patient must be able to adhere to the visit schedule as outlined in the study and follow protocol requirements.
- •12. ECOG performance status 0-2 at the time of screening.
- •13. A FCBP (female of childbearing potential) for this study was defined as a sexually mature woman who: (1) had not undergone a hysterectomy or bilateral oophorectomy; or (2) had not been naturally postmenopausal (amenorrhea following cancer therapy did not rule out childbearing potential) for at least 24 consecutive months (ie, has had menses at any time in the preceding 24 consecutive months). A FCBP participating in the study must:
- •a) Have had 2 negative pregnancy tests as verified by the investigator prior to starting IP (unless the screening pregnancy test was done within 72 hours of Cycle 1 Day 1). She must have had agreed to ongoing pregnancy testing during the course of the study and after EOT
- •b) If sexually active, agreed to have used, and been able to comply with, highly effective contraception** without interruption, 5 weeks prior to starting IP, during treatment with IP (including dose interruptions), and for 12 weeks after discontinuation of IP.
- •o ** Highly effective contraception was defined in this protocol as the following (information also appeared in the ICF): Hormonal contraception (eg, birth control pills, injection, implant, transdermal patch, vaginal ring), intrauterine device, tubal ligation (tying your tubes), or a partner with a vasectomy
- •Male subjects must: Have agreed to use a condom, defined as a male latex condom or nonlatex condom NOT made out of natural (animal) membrane (eg, polyurethane), during sexual contact with a pregnant female or a FCBP while participating in the study, during dose interruptions, and for at least 12 weeks following IP discontinuation, even if he had undergone a successful vasectomy
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 150
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 150
排除标准
- •A patient meeting any of the following criteria is not eligible to participate in the study:
- •1. Severe infection or any other uncontrolled severe condition.
- •2. Significant cardiac disease - NYHA Class III or IV or having suffered a myocardial infarction in the last 6 months.
- •3. del(5q) syndrome
- •4. Use of investigational agents within 30 days or any anticancer therapy (including IMiD) within 2 weeks before the study entry with the exception of hydroxyurea. The patient must have recovered from all acute toxicity from any previous therapy.
- •5. Active cancer, or cancer during the year prior to trial entry other than basal cell carcinoma, or carcinoma in situ of the cervix or breast.
- •6. Patient already enrolled in another therapeutic trial of an investigational drug.
- •7. Known HIV infection or active hepatitis B or C.
- •8. Women who are or could become pregnant or who are currently breastfeeding.
- •9. Any medical or psychiatric contraindication that would prevent the patient from understanding and signing the informed consent form.
- •10. Patient eligible for allogeneic stem cell transplantation.
- •11. Known allergies to luspatercept or EPO or any of its excipients.
- •12. No affiliation to a health insurance system.
研究者
相似试验
进行中（未招募）
1 期
A multicentric randomized phase II study evaluating dual targeting of the EGFR using the combination of cetuximab and afatinib versus cetuximab alone in patients with chemotherapy refractory wtKRAS metastatic colorectal cancer.Refractory wtKRAS metastatic colorectal cancerMedDRA version: 14.1 Level: LLT Classification code 10052362 Term: Metastatic colorectal cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-000167-25-FRICANCER75
进行中（未招募）
1 期
Clinical Trial to study the effect of the treatment with eribulin and endocrine therapy in metastatic breast cancer patientsuminal Metastatic Breast CancerMedDRA version: 20.0 Level: LLT Classification code 10027475 Term: Metastatic breast cancer System Organ Class: 100000004864MedDRA version: 20.1 Level: LLT Classification code 10070575 Term: Estrogen receptor positive breast cancer System Organ Class: 100000004864EUCTR2017-004324-30-ESMedica Scientia Innovation Research (MEDSIR)60
进行中（未招募）
不适用
A Phase II, randomised, multicentre study to evaluate the efficacy and safety of pazopanib in combination with pemetrexed versus cisplatin plus pemetrexed, as first-line therapy in subjects with stage IIIB/IV non-small cell lung cancerHistologically- or cytologically-confirmed diagnosis of non-predominantly squamous cell Stage IIIBwet (with confirmed malignant pleural effusion) or Stage IV NSCLCMedDRA version: 9.1Level: LLTClassification code 10029521Term: Non-small cell lung cancer stage IIIBMedDRA version: 9.1Level: LLTClassification code 10029522Term: Non-small cell lung cancer stage IVEUCTR2008-002144-42-DKGlaxoSmithKline R&D Limited150
进行中（未招募）
不适用
A Phase II, randomised, multicentre study to evaluate the efficacy and safety of pazopanib in combination with pemetrexed versus cisplatin plus pemetrexed, as first-line therapy in subjects with stage IIIB/IV non-small cell lung cancerHistologically- or cytologically-confirmed diagnosis of non-predominantly squamous cell Stage IIIBwet (with confirmed malignant pleural effusion) or Stage IV NSCLCMedDRA version: 9.1Level: LLTClassification code 10029521Term: Non-small cell lung cancer stage IIIBMedDRA version: 9.1Level: LLTClassification code 10029522Term: Non-small cell lung cancer stage IVEUCTR2008-002144-42-DEGlaxoSmithKline R&D Limited150
进行中（未招募）
不适用
A Phase II, randomised, multicentre study to evaluate the efficacy and safety of pazopanib in combination with pemetrexed versus cisplatin plus pemetrexed, as first-line therapy in subjects with stage IIIB/IV non-small cell lung cancerHistologically- or cytologically-confirmed diagnosis of non-predominantly squamous cell Stage IIIBwet (with confirmed malignant pleural effusion) or Stage IV NSCLCMedDRA version: 9.1Level: LLTClassification code 10029521Term: Non-small cell lung cancer stage IIIBMedDRA version: 9.1Level: LLTClassification code 10029522Term: Non-small cell lung cancer stage IVEUCTR2008-002144-42-NLGlaxoSmithKline R&D Limited150